Pulmonary Fibrosis Clinical Trials
Here are the 6 most popular medical studies for pulmonary fibrosis
LYT-100 (Deupirfenidone) for Idiopathic Pulmonary Fibrosis
ELEVATE is testing a new investigational drug, LYT-100, to see if it has improved safety (better tolerated) than one of the currently approved treatments for idiopathic pulmonary fibrosis, pirfenidone, and to demonstrate if it has improved efficacy (works better) than a placebo.
Popular filter options for pulmonary fibrosis trials
Idiopathic Pulmonary Fibrosis Clinical Trials
View 53 Idiopathic Pulmonary Fibrosis medical studies.
Procedure
BIO 300 Oral Suspension for Post-COVID Syndrome
This trial is testing whether BIO 300 Oral Suspension can improve lung function in patients who were hospitalized for severe COVID-19 and continue to experience post-acute respiratory complications. Patients will be randomly assigned to receive either BIO 300 or a placebo.
IPF Clinical Trials
View 40 IPF medical studies.
Xenon MRI for Idiopathic Pulmonary Fibrosis
This trial is being done to see if MRI using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments.
Phase 3 Pulmonary Fibrosis Clinical Trials
View 56 phase 3 pulmonary fibrosis medical studies.
Mucolytic Agent
N-acetyl Cysteine for Idiopathic Pulmonary Fibrosis
This trial will compare the effect of NAC plus standard care with placebo plus standard of care in patients with idiopathic pulmonary fibrosis who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function, first respiratory hospitalization, lung transplantation, or all-cause mortality.
Pulmonary Fibrosis Clinical Trials With No Placebo
View 56 pulmonary fibrosis medical studies that do not have a placebo group.
Xenon MRI for Idiopathic Pulmonary Fibrosis
This trial is being done to see if MRI using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments.
View More Pulmonary Fibrosis Trials
See another 32 medical studies focused on pulmonary fibrosis.
Frequently Asked Questions
Introduction to pulmonary fibrosis
What are the top hospitals conducting pulmonary fibrosis research?
Pulmonary fibrosis is a chronic and progressive lung disease that affects thousands of people worldwide, causing scarring and thickening of the lungs. In the quest to find effective treatments for this debilitating condition, several top hospitals have emerged as leaders in conducting groundbreaking clinical trials. One such institution is the Southeastern Research Center located in Winston-Salem. With an impressive 11 ongoing pulmonary fibrosis trials and a total of 12 completed trials since their first recorded trial in 2020, they are dedicated to advancing our understanding and treatment options for this disease.
Meanwhile, the University of Kansas Medical Center in Kansas City has also made significant contributions to pulmonary fibrosis research. Currently overseeing eight active clinical trials and having conducted a remarkable total of 19 studies since their inaugural trial in 2013, they are at the forefront of exploring innovative therapies for patients battling this condition.
In Boston's renowned Massachusetts General Hospital, researchers are working tirelessly on six active clinical trials related to pulmonary fibrosis. Their commitment extends beyond these current endeavors as they have already completed an impressive tally of 20 previous studies since launching their pioneering trial back in 2011.
The Medical University of South carolina based in Charleston is another leading hospital making strides towards better understanding and treating pulmonary fibrosis. They currently oversee six active clinical trials while boasting an incredible history consisting of 31 previous investigations dating back to their initial study on this condition recorded in 2007.
Rounding out this list is Vanderbilt University Medical Center situated in Nashville where researchers are actively involved with six ongoing pulmonary fibrosis trials along with contributing significantly through its thirty previously held investigations; it all started with their first recorded pulmonary fibrosis trial way back into the year2003
These institutions epitomize dedication and progress within the field by pushing boundaries through rigorous research efforts aimed at improving outcomes for individuals affected by pulmonary fibrosis globally. Each step forward brings hope closer for those living with this challenging respiratory disorder.
Which are the best cities for pulmonary fibrosis clinical trials?
When it comes to pulmonary fibrosis clinical trials, several cities in the United States are at the forefront of research and advancements. Philadelphia, Pennsylvania leads with 22 active trials exploring treatments like Inhaled Treprostinil, Long Term Follow Up, and BMS-986278 Dose 1. Los Angeles, California and Dallas, Texas closely follow with 20 ongoing studies investigating interventions such as Inhaled Treprostinil, N-acetyl cysteine, and CSL312. Birmingham, Alabama also shows promising progress with 16 active trials focusing on Inhaled Treprostinil, BMS-986278 Dose 1, and Deupirfenidone. Additionally, New york City contributes significantly to the field with its 15 ongoing trials examining treatment options like Nintedanib and β-lactam Only (Non-AG). These cities serve as key hubs for individuals seeking participation in cutting-edge pulmonary fibrosis clinical trials that offer hope for improved outcomes.
Which are the top treatments for pulmonary fibrosis being explored in clinical trials?
Pulmonary fibrosis, a challenging condition affecting the lungs, has seen promising developments in clinical trials exploring potential treatments. Inhaled Treprostinil leads the pack with three active trials and six all-time pulmonary fibrosis trials since its introduction in 2016. Following closely is INS018_055, currently being tested in two active trials and featured in three all-time pulmonary fibrosis studies since 2022. Not to be overlooked is EV-Pure™ and WJ-Pure™ alongside standard care, showing promise with one ongoing trial and one previous trial listed this year. These advancements bring hope for improved management of pulmonary fibrosis, fostering optimism for patients dealing with this debilitating disease.
What are the most recent clinical trials for pulmonary fibrosis?
Exciting advancements are underway in the realm of pulmonary fibrosis as recent clinical trials offer hope and potential breakthroughs. Notably, BMS-986278 Dose 1 has entered Phase 3 trials, showcasing its promise as a treatment option for this condition. Additionally, Leramistat is being evaluated in Phase 2 trials to assess its efficacy against pulmonary fibrosis. Preliminary studies have also explored the combination therapy of EGCG 600 mg with Pirfenidone in Phase 1 trials, highlighting a potential avenue for improved outcomes. Lastly, sodium pyruvate nasal spray treatment is currently being investigated in Phase 3 trials for its impact on mitigating symptoms associated with pulmonary fibrosis. These ongoing initiatives demonstrate a collective dedication towards enhancing the lives of those affected by this challenging lung disease.
What pulmonary fibrosis clinical trials were recently completed?
In November 2021, AstraZeneca concluded a trial for AZD5055, representing a significant step in the pursuit of effective treatments for pulmonary fibrosis. Additionally, Pulmonary Research of Abingdon recently completed a trial investigating Pirfenidone in August 2020. These studies join the ranks of other completed trials such as PLN-74809 by Pliant Therapeutics (March 2020), NIP292 tablets by The National Institutes of Pharmaceutical R&D Co. Ltd (November 2019), GB0139 by Galecto Biotech AB (February 2019), TRK-250 by Toray Industries Inc (November 2018), ND-L02-s0201 by Nitto Denko Corporation (June 2018) and Epigallocatechin-3-gallate (EGCG) conducted at the University of California San Francisco in December 2017. Their completion represents significant progress in our ongoing battle against this debilitating condition known as pulmonary fibrosis.